Kidney disease

Monoclonal antibody
#Bayer #Evotec #Kidney disease #Monoclonal antibodies #Phase I trial

First patient dosed in trial of antibody for kidney disease

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (mAb) targeting the protein Semaphorin-3A (Sema3A), is being developed as a potential first-to-market… Read More

#News

Patient receiving dialysis treatment
#Chronic kidney disease (CKD) #FDA #GSK #Kidney disease

New oral option for anaemia of CKD approved in US

The US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.   Jesduvroq is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the US. … Read More

#News #Regulatory

Identifying bacteria in the lab
#Abionyx Pharma #Gram-negative bacteria #Kidney disease #Phase II trial #Sepsis

New drug reduced renal damage in septic patients

A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint.  The RACERS study included 20 patients with gram-negative sepsis who were at high risk for acute kidney… Read More

#Editor's Choice #News

#European Commission #Kidney disease #Nephrology #Orphan drugs

EC approves first treatment for rare kidney disease

Nefecon has become the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive kidney disease. The European Medicines Agency said that the medicine “was shown to be effective at lowering the level of excess protein in the urine in patients with IgAN,… Read More

#News #Regulatory